Condition
Thymoma Type B3
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04710628Phase 2Completed
Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents
NCT03134118Phase 2UnknownPrimary
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
NCT02307500Phase 2Completed
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
Showing all 3 trials